BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors Read more
FDA Approves Merck’s KEYTRUDA (pembrolizumab) in Combination With Padcev (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer Read more
License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed Read more
GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection Read more
Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility Read more
GenesisCare and PreMIT Collaborate to Identify and Pursue Clinical Research Opportunities in Theranostics and Molecular Imaging Read more
FDA Grants Full Approval to KEYTRUDA (pembrolizumab) for Advanced MSI-H or dMMR Solid Tumors in Adults and Children Read more
Lupus Research Alliance Unites the U.S. Food & Drug Administration (FDA) & Lupus Community to Launch Novel Public-Private Partnership Read more